How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "8442"
  ["article_id"]=>
  string(4) "8442"
  [1]=>
  string(58) "A record high for life science patent applications in 2019"
  ["article_title"]=>
  string(58) "A record high for life science patent applications in 2019"
  [2]=>
  string(150) "Statistics published by the European Patent Office (EPO) show that the number of patents filed by companies and researchers in the life sciences secto"
  ["short_description"]=>
  string(150) "Statistics published by the European Patent Office (EPO) show that the number of patents filed by companies and researchers in the life sciences secto"
  [3]=>
  string(182) "Statistics published by the European Patent Office (EPO) show that the number of patents filed by companies and researchers in the life sciences sectors has grown over the past year."
  ["description"]=>
  string(182) "Statistics published by the European Patent Office (EPO) show that the number of patents filed by companies and researchers in the life sciences sectors has grown over the past year."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(102) "https://www.medicalplasticsnews.com/news/a-record-high-for-life-science-patent-applications-over-the-/"
  ["blog_url"]=>
  string(102) "https://www.medicalplasticsnews.com/news/a-record-high-for-life-science-patent-applications-over-the-/"
  [15]=>
  string(19) "2020-03-12 19:08:00"
  ["add_date"]=>
  string(19) "2020-03-12 19:08:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:35"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:35"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

A record high for life science patent applications in 2019

Statistics published by the European Patent Office (EPO) show that the number of patents filed by companies and research

array(40) {
  [0]=>
  string(4) "8409"
  ["article_id"]=>
  string(4) "8409"
  [1]=>
  string(44) "The Ingredients Show postponed to April 2021"
  ["article_title"]=>
  string(44) "The Ingredients Show postponed to April 2021"
  [2]=>
  string(124) "In light of the ongoing COVID-19 health situation, William Reed Business Media has decided to postpone The Ingredients Show."
  ["short_description"]=>
  string(124) "In light of the ongoing COVID-19 health situation, William Reed Business Media has decided to postpone The Ingredients Show."
  [3]=>
  string(124) "In light of the ongoing COVID-19 health situation, William Reed Business Media has decided to postpone The Ingredients Show."
  ["description"]=>
  string(124) "In light of the ongoing COVID-19 health situation, William Reed Business Media has decided to postpone The Ingredients Show."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "35"
  ["rss_id"]=>
  string(2) "35"
  [14]=>
  string(145) "https://www.foodnavigator.com/Article/2020/03/12/The-Ingredients-Show-postponed-to-April-2021?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(145) "https://www.foodnavigator.com/Article/2020/03/12/The-Ingredients-Show-postponed-to-April-2021?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2020-03-12 18:46:00"
  ["add_date"]=>
  string(19) "2020-03-12 18:46:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

The Ingredients Show postponed to April 2021

In light of the ongoing COVID-19 health situation, William Reed Business Media has decided to postpone The Ingredients S

array(40) {
  [0]=>
  string(4) "8424"
  ["article_id"]=>
  string(4) "8424"
  [1]=>
  string(70) "Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic"
  ["article_title"]=>
  string(70) "Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic"
  [2]=>
  string(155) "Reuse and recycle is more than an environmental slogan. It’s also a succinct description of how cells deal with old or damaged proteins. Kymera Ther"
  ["short_description"]=>
  string(155) "Reuse and recycle is more than an environmental slogan. It’s also a succinct description of how cells deal with old or damaged proteins. Kymera Ther"
  [3]=>
  string(345) "Reuse and recycle is more than an environmental slogan. It’s also a succinct description of how cells deal with old or damaged proteins. Kymera Therapeutics is developing drugs that use this cyclical cellular process to treat disease, and it has raised $102 million to move into clinical testing next year. The Series C round of […]"
  ["description"]=>
  string(345) "Reuse and recycle is more than an environmental slogan. It’s also a succinct description of how cells deal with old or damaged proteins. Kymera Therapeutics is developing drugs that use this cyclical cellular process to treat disease, and it has raised $102 million to move into clinical testing next year. The Series C round of […]"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "36"
  ["rss_id"]=>
  string(2) "36"
  [14]=>
  string(108) "https://xconomy.com/boston/2020/03/12/kymera-closes-102m-round-to-bring-protein-busting-drugs-to-the-clinic/"
  ["blog_url"]=>
  string(108) "https://xconomy.com/boston/2020/03/12/kymera-closes-102m-round-to-bring-protein-busting-drugs-to-the-clinic/"
  [15]=>
  string(19) "2020-03-12 17:00:53"
  ["add_date"]=>
  string(19) "2020-03-12 17:00:53"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:27"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic

Reuse and recycle is more than an environmental slogan. It’s also a succinct description of how cells deal with o

array(40) {
  [0]=>
  string(4) "8239"
  ["article_id"]=>
  string(4) "8239"
  [1]=>
  string(100) "Swedish Healthcare Provider Orders Sectra's Imaging IT Solution for Radiology as a Cloud Service"
  ["article_title"]=>
  string(100) "Swedish Healthcare Provider Orders Sectra's Imaging IT Solution for Radiology as a Cloud Service"
  [2]=>
  string(153) "LINKÖPING, Sweden, March 12, 2020 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a contra"
  ["short_description"]=>
  string(153) "LINKÖPING, Sweden, March 12, 2020 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a contra"
  [3]=>
  string(300) "
LINKÖPING, Sweden, March 12, 2020 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a contract with the Swedish healthcare provider Region Halland to deliver its radiology imaging solution as a cloud service. The new service will...
"
  ["description"]=>
  string(300) "
LINKÖPING, Sweden, March 12, 2020 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed a contract with the Swedish healthcare provider Region Halland to deliver its radiology imaging solution as a cloud service. The new service will...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(155) "https://www.prnewswire.com:443/news-releases/swedish-healthcare-provider-orders-sectras-imaging-it-solution-for-radiology-as-a-cloud-service-301022126.html"
  ["blog_url"]=>
  string(155) "https://www.prnewswire.com:443/news-releases/swedish-healthcare-provider-orders-sectras-imaging-it-solution-for-radiology-as-a-cloud-service-301022126.html"
  [15]=>
  string(19) "2020-03-12 15:50:00"
  ["add_date"]=>
  string(19) "2020-03-12 15:50:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:01"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:01"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Swedish Healthcare Provider Orders Sectra's Imaging IT Solution for Radiology as a Clo

LINKÖPING, Sweden, March 12, 2020 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sect

array(40) {
  [0]=>
  string(4) "8240"
  ["article_id"]=>
  string(4) "8240"
  [1]=>
  string(102) "2020 Filtration & Separation Asia to be held at Shanghai New International Expo Center in December"
  ["article_title"]=>
  string(102) "2020 Filtration & Separation Asia to be held at Shanghai New International Expo Center in December"
  [2]=>
  string(150) "SHANGHAI, March 12, 2020 /PRNewswire/ -- The 8th Filtration & Separation Asia (FSA 2020), cohosted by Informa Markets, which also is the 11th China In"
  ["short_description"]=>
  string(150) "SHANGHAI, March 12, 2020 /PRNewswire/ -- The 8th Filtration & Separation Asia (FSA 2020), cohosted by Informa Markets, which also is the 11th China In"
  [3]=>
  string(303) "
SHANGHAI, March 12, 2020 /PRNewswire/ -- The 8th Filtration & Separation Asia (FSA 2020), cohosted by Informa Markets, which also is the 11th China International Filtration & Separation Exhibition will be held at Shanghai New International Expo Center from 9 – 11 Dec, 2020 in Shanghai,...
"
  ["description"]=>
  string(303) "
SHANGHAI, March 12, 2020 /PRNewswire/ -- The 8th Filtration & Separation Asia (FSA 2020), cohosted by Informa Markets, which also is the 11th China International Filtration & Separation Exhibition will be held at Shanghai New International Expo Center from 9 – 11 Dec, 2020 in Shanghai,...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(157) "https://www.prnewswire.com:443/news-releases/2020-filtration--separation-asia-to-be-held-at-shanghai-new-international-expo-center-in-december-301021430.html"
  ["blog_url"]=>
  string(157) "https://www.prnewswire.com:443/news-releases/2020-filtration--separation-asia-to-be-held-at-shanghai-new-international-expo-center-in-december-301021430.html"
  [15]=>
  string(19) "2020-03-12 15:30:00"
  ["add_date"]=>
  string(19) "2020-03-12 15:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:01"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:01"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

2020 Filtration & Separation Asia to be held at Shanghai New International Expo Center

SHANGHAI, March 12, 2020 /PRNewswire/ -- The 8th Filtration & Separation Asia (FSA 2020), cohosted by Informa Markets

array(40) {
  [0]=>
  string(4) "8241"
  ["article_id"]=>
  string(4) "8241"
  [1]=>
  string(83) "Castellum Takes Measures to Reduce Risk of Spreading Covid-19 Virus at March 19 AGM"
  ["article_title"]=>
  string(83) "Castellum Takes Measures to Reduce Risk of Spreading Covid-19 Virus at March 19 AGM"
  [2]=>
  string(150) "GOTHENBURG, Sweden, March 12, 2020 /PRNewswire/ -- Transmission speed of the Covid-19 (corona) virus remains difficult to assess, and Castellum is clo"
  ["short_description"]=>
  string(150) "GOTHENBURG, Sweden, March 12, 2020 /PRNewswire/ -- Transmission speed of the Covid-19 (corona) virus remains difficult to assess, and Castellum is clo"
  [3]=>
  string(298) "
GOTHENBURG, Sweden, March 12, 2020 /PRNewswire/ -- Transmission speed of the Covid-19 (corona) virus remains difficult to assess, and Castellum is closely following developments. With a view to shielding the health of shareholders, Board members and co-workers, several new decisions have...
"
  ["description"]=>
  string(298) "
GOTHENBURG, Sweden, March 12, 2020 /PRNewswire/ -- Transmission speed of the Covid-19 (corona) virus remains difficult to assess, and Castellum is closely following developments. With a view to shielding the health of shareholders, Board members and co-workers, several new decisions have...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(143) "https://www.prnewswire.com:443/news-releases/castellum-takes-measures-to-reduce-risk-of-spreading-covid-19-virus-at-march-19-agm-301022116.html"
  ["blog_url"]=>
  string(143) "https://www.prnewswire.com:443/news-releases/castellum-takes-measures-to-reduce-risk-of-spreading-covid-19-virus-at-march-19-agm-301022116.html"
  [15]=>
  string(19) "2020-03-12 15:29:00"
  ["add_date"]=>
  string(19) "2020-03-12 15:29:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:01"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:01"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Castellum Takes Measures to Reduce Risk of Spreading Covid-19 Virus at March 19 AGM

GOTHENBURG, Sweden, March 12, 2020 /PRNewswire/ -- Transmission speed of the Covid-19 (corona) virus remains difficul

array(40) {
  [0]=>
  string(4) "8242"
  ["article_id"]=>
  string(4) "8242"
  [1]=>
  string(96) "Suning International Donates Medical Masks to Italy to Support the Fight Against the Coronavirus"
  ["article_title"]=>
  string(96) "Suning International Donates Medical Masks to Italy to Support the Fight Against the Coronavirus"
  [2]=>
  string(150) "NANJING, China, March 12, 2020 /PRNewswire/ -- Suning International announced that it will donate the first 300 thousand medical masks and other healt"
  ["short_description"]=>
  string(150) "NANJING, China, March 12, 2020 /PRNewswire/ -- Suning International announced that it will donate the first 300 thousand medical masks and other healt"
  [3]=>
  string(293) "
NANJING, China, March 12, 2020 /PRNewswire/ -- Suning International announced that it will donate the first 300 thousand medical masks and other healthcare products, such as protective garment and disinfection products, to support Italy to fight against the coronavirus, based on its...
"
  ["description"]=>
  string(293) "
NANJING, China, March 12, 2020 /PRNewswire/ -- Suning International announced that it will donate the first 300 thousand medical masks and other healthcare products, such as protective garment and disinfection products, to support Italy to fight against the coronavirus, based on its...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(156) "https://www.prnewswire.com:443/news-releases/suning-international-donates-medical-masks-to-italy-to-support-the-fight-against-the-coronavirus-301022098.html"
  ["blog_url"]=>
  string(156) "https://www.prnewswire.com:443/news-releases/suning-international-donates-medical-masks-to-italy-to-support-the-fight-against-the-coronavirus-301022098.html"
  [15]=>
  string(19) "2020-03-12 14:16:00"
  ["add_date"]=>
  string(19) "2020-03-12 14:16:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:01"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:01"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Suning International Donates Medical Masks to Italy to Support the Fight Against the Coron

NANJING, China, March 12, 2020 /PRNewswire/ -- Suning International announced that it will donate the first 300 thous

array(40) {
  [0]=>
  string(4) "8243"
  ["article_id"]=>
  string(4) "8243"
  [1]=>
  string(156) "Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease Therapies"
  ["article_title"]=>
  string(156) "Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease Therapies"
  [2]=>
  string(150) "TEL AVIV, Israel, March 12, 2020 /PRNewswire/ -- Everads Therapy, an early-stage life sciences company developing the next generation of retinal treat"
  ["short_description"]=>
  string(150) "TEL AVIV, Israel, March 12, 2020 /PRNewswire/ -- Everads Therapy, an early-stage life sciences company developing the next generation of retinal treat"
  [3]=>
  string(294) "
TEL AVIV, Israel, March 12, 2020 /PRNewswire/ -- Everads Therapy, an early-stage life sciences company developing the next generation of retinal treatment delivery technologies, today announced that it has signed an option agreement with a large global pharmaceutical company. This is...
"
  ["description"]=>
  string(294) "
TEL AVIV, Israel, March 12, 2020 /PRNewswire/ -- Everads Therapy, an early-stage life sciences company developing the next generation of retinal treatment delivery technologies, today announced that it has signed an option agreement with a large global pharmaceutical company. This is...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(211) "https://www.prnewswire.com:443/news-releases/everads-therapy-enters-into-option-agreement-with-global-pharma-company-to-license-everads-suprachoroidal-delivery-system-for-retinal-disease-therapies-301021829.html"
  ["blog_url"]=>
  string(211) "https://www.prnewswire.com:443/news-releases/everads-therapy-enters-into-option-agreement-with-global-pharma-company-to-license-everads-suprachoroidal-delivery-system-for-retinal-disease-therapies-301021829.html"
  [15]=>
  string(19) "2020-03-12 14:00:00"
  ["add_date"]=>
  string(19) "2020-03-12 14:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:01"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:01"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads

TEL AVIV, Israel, March 12, 2020 /PRNewswire/ -- Everads Therapy, an early-stage life sciences company developing the

array(40) {
  [0]=>
  string(4) "8226"
  ["article_id"]=>
  string(4) "8226"
  [1]=>
  string(123) "Engage Therapeutics Announces Phase 2b StATES Study of Staccato® Alprazolam for Seizure Cessation Meets Primary Endpoint"
  ["article_title"]=>
  string(123) "Engage Therapeutics Announces Phase 2b StATES Study of Staccato® Alprazolam for Seizure Cessation Meets Primary Endpoint"
  [2]=>
  string(150) "-- Staccato alprazolam achieved statistically significant response rate in both treatment arms compared to placebo ---- Average time to seizure cessat"
  ["short_description"]=>
  string(150) "-- Staccato alprazolam achieved statistically significant response rate in both treatment arms compared to placebo ---- Average time to seizure cessat"
  [3]=>
  string(1119) "
-- Staccato alprazolam achieved statistically significant response rate in both treatment arms compared to placebo --
-- Average time to seizure cessation was 30 seconds --
-- Staccato alprazolam generally well-tolerated --
-- Data to be presented at American Academy of Neurology on April 26 --
 
SUMMIT, N.J., March  12, 2020  (GLOBE NEWSWIRE) -- Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing an orally inhaled therapy designed to terminate an active epileptic seizure, today announced that its Phase 2b StATES study of Staccato® alprazolam met its primary endpoint which was proportion of responders achieving cessation of seizure activity within two minutes of treatment administration and no recurrence within two hours.
"
  ["description"]=>
  string(1119) "
-- Staccato alprazolam achieved statistically significant response rate in both treatment arms compared to placebo --
-- Average time to seizure cessation was 30 seconds --
-- Staccato alprazolam generally well-tolerated --
-- Data to be presented at American Academy of Neurology on April 26 --
 
SUMMIT, N.J., March  12, 2020  (GLOBE NEWSWIRE) -- Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing an orally inhaled therapy designed to terminate an active epileptic seizure, today announced that its Phase 2b StATES study of Staccato® alprazolam met its primary endpoint which was proportion of responders achieving cessation of seizure activity within two minutes of treatment administration and no recurrence within two hours.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(190) "http://www.globenewswire.com/news-release/2020/03/12/1999155/0/en/Engage-Therapeutics-Announces-Phase-2b-StATES-Study-of-Staccato-Alprazolam-for-Seizure-Cessation-Meets-Primary-Endpoint.html"
  ["blog_url"]=>
  string(190) "http://www.globenewswire.com/news-release/2020/03/12/1999155/0/en/Engage-Therapeutics-Announces-Phase-2b-StATES-Study-of-Staccato-Alprazolam-for-Seizure-Cessation-Meets-Primary-Endpoint.html"
  [15]=>
  string(19) "2020-03-12 12:02:00"
  ["add_date"]=>
  string(19) "2020-03-12 12:02:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:55:49"
  ["create_at"]=>
  string(19) "2020-03-12 15:55:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Engage Therapeutics Announces Phase 2b StATES Study of Staccato® Alprazolam for Seizure

-- Staccato alprazolam achieved statistically significant response rate in both treatment 

array(40) {
  [0]=>
  string(4) "8244"
  ["article_id"]=>
  string(4) "8244"
  [1]=>
  string(51) "Boston Consulting Group Revenues Reach $8.5 Billion"
  ["article_title"]=>
  string(51) "Boston Consulting Group Revenues Reach $8.5 Billion"
  [2]=>
  string(154) "BOSTON, March 12, 2020 /PRNewswire/ -- Boston Consulting Group (BCG), one of the world's leading management consulting firms, announced today global s"
  ["short_description"]=>
  string(154) "BOSTON, March 12, 2020 /PRNewswire/ -- Boston Consulting Group (BCG), one of the world's leading management consulting firms, announced today global s"
  [3]=>
  string(307) "
BOSTON, March 12, 2020 /PRNewswire/ -- Boston Consulting Group (BCG), one of the world's leading management consulting firms, announced today global sales of $8.5 billion for 2019, with underlying revenue growth of 14% at constant exchange rates. From 2009 to 2019, BCG's global sales grew...
"
  ["description"]=>
  string(307) "
BOSTON, March 12, 2020 /PRNewswire/ -- Boston Consulting Group (BCG), one of the world's leading management consulting firms, announced today global sales of $8.5 billion for 2019, with underlying revenue growth of 14% at constant exchange rates. From 2009 to 2019, BCG's global sales grew...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(110) "https://www.prnewswire.com:443/news-releases/boston-consulting-group-revenues-reach-8-5-billion-301021979.html"
  ["blog_url"]=>
  string(110) "https://www.prnewswire.com:443/news-releases/boston-consulting-group-revenues-reach-8-5-billion-301021979.html"
  [15]=>
  string(19) "2020-03-12 12:01:00"
  ["add_date"]=>
  string(19) "2020-03-12 12:01:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:01"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:01"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Boston Consulting Group Revenues Reach $8.5 Billion

BOSTON, March 12, 2020 /PRNewswire/ -- Boston Consulting Group (BCG), one of the world's leading management consu

array(40) {
  [0]=>
  string(4) "8245"
  ["article_id"]=>
  string(4) "8245"
  [1]=>
  string(73) "Statement from Nicholas E. Calio, President and CEO, Airlines for America"
  ["article_title"]=>
  string(73) "Statement from Nicholas E. Calio, President and CEO, Airlines for America"
  [2]=>
  string(150) "WASHINGTON, March 11, 2020 /PRNewswire/ -- A4A President and CEO Nicholas E. Calio issued the following statement this evening: We commend President T"
  ["short_description"]=>
  string(150) "WASHINGTON, March 11, 2020 /PRNewswire/ -- A4A President and CEO Nicholas E. Calio issued the following statement this evening: We commend President T"
  [3]=>
  string(297) "
WASHINGTON, March 11, 2020 /PRNewswire/ -- A4A President and CEO Nicholas E. Calio issued the following statement this evening: We commend President Trump for continuing to take decisive action to protect the health and well-being of the American people. For U.S. airlines, the safety of...
"
  ["description"]=>
  string(297) "
WASHINGTON, March 11, 2020 /PRNewswire/ -- A4A President and CEO Nicholas E. Calio issued the following statement this evening: We commend President Trump for continuing to take decisive action to protect the health and well-being of the American people. For U.S. airlines, the safety of...
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "28"
  ["rss_id"]=>
  string(2) "28"
  [14]=>
  string(130) "https://www.prnewswire.com:443/news-releases/statement-from-nicholas-e-calio-president-and-ceo-airlines-for-america-301022065.html"
  ["blog_url"]=>
  string(130) "https://www.prnewswire.com:443/news-releases/statement-from-nicholas-e-calio-president-and-ceo-airlines-for-america-301022065.html"
  [15]=>
  string(19) "2020-03-12 11:58:00"
  ["add_date"]=>
  string(19) "2020-03-12 11:58:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:01"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:01"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Statement from Nicholas E. Calio, President and CEO, Airlines for America

WASHINGTON, March 11, 2020 /PRNewswire/ -- A4A President and CEO Nicholas E. Calio issued the following statement thi

array(40) {
  [0]=>
  string(4) "8227"
  ["article_id"]=>
  string(4) "8227"
  [1]=>
  string(50) "IMARA Announces Pricing of Initial Public Offering"
  ["article_title"]=>
  string(50) "IMARA Announces Pricing of Initial Public Offering"
  [2]=>
  string(158) "BOSTON, March  11, 2020  (GLOBE NEWSWIRE) -- IMARA Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to de"
  ["short_description"]=>
  string(158) "BOSTON, March  11, 2020  (GLOBE NEWSWIRE) -- IMARA Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to de"
  [3]=>
  string(978) "
BOSTON, March  11, 2020  (GLOBE NEWSWIRE) -- IMARA Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, announced the pricing of its initial public offering of 4,700,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $75.2 million, before underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on March 16, 2020, subject to customary closing conditions. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase up to 705,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered by the Company. 
"
  ["description"]=>
  string(978) "
BOSTON, March  11, 2020  (GLOBE NEWSWIRE) -- IMARA Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, announced the pricing of its initial public offering of 4,700,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $75.2 million, before underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on March 16, 2020, subject to customary closing conditions. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase up to 705,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered by the Company. 
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(121) "http://www.globenewswire.com/news-release/2020/03/12/1999138/0/en/IMARA-Announces-Pricing-of-Initial-Public-Offering.html"
  ["blog_url"]=>
  string(121) "http://www.globenewswire.com/news-release/2020/03/12/1999138/0/en/IMARA-Announces-Pricing-of-Initial-Public-Offering.html"
  [15]=>
  string(19) "2020-03-12 09:57:00"
  ["add_date"]=>
  string(19) "2020-03-12 09:57:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:55:49"
  ["create_at"]=>
  string(19) "2020-03-12 15:55:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

IMARA Announces Pricing of Initial Public Offering

BOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage